Peptides Explained

The State of Peptides 2026 | Clinician Webinar

The peptide landscape is changing rapidly. New research is emerging, regulatory decisions continue to shape clinical practice, and healthcare providers are being asked more questions than ever before.

Join Peptide Solutions for a live clinician-focused webinar covering the current state of peptides in 2026. This educational session is designed for physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other healthcare professionals interested in understanding the latest developments.

• The current peptide and GLP-1 landscape • Recent FDA and PCAC regulatory updates • The most commonly discussed therapeutic peptides • Current evidence and clinical data • Safety, quality, and sourcing considerations • What providers should expect moving forward

📅 August 13, 2026 🕖 7:00 PM Central Time

Register: https://peptide-solutions.info

This webinar is intended for educational purposes only. Peptide Solutions does not diagnose, treat, prescribe, compound, or dispense medications. Prescription therapies require evaluation and oversight by a licensed healthcare provider. Discussions of research peptides are for educational purposes only and should not be interpreted as recommendations for human use.

After researching peptide science week after week—and using some compounds personally—I'm answering one of the most common questions I receive: Which peptides do I find the most useful and compelling?

This is not a universal ranking or a recommendation to use all 11. Tirzepatide, retatrutide, tesamorelin, ipamorelin, BPC-157, TB-500, GHK-Cu, KPV, PT-141, MOTS-c, and SS-31 occupy very different evidence and regulatory categories. Some are FDA-approved prescription drugs. Some have encouraging human data. Others remain experimental and are supported mainly by animal, cell, mechanistic, or anecdotal evidence.

In this episode, we examine the problem each peptide is intended to solve, how it works, what the human evidence shows, where the evidence is weak, known risks, regulatory status, and why each compound made my personal list.

This episode is for education and discussion only. It is not medical advice. Always involve a qualified healthcare professional before starting, stopping, or changing a therapy.

Peptides Explained is an affiliate partner with OfflinePeptides.com.

Visit PeptidesExplained.info/OfflinePeptides.

For Peptides through a compounding pharmacy or a telehealth option

Visit Peptide-Solutions.info and submit a request for more information.

GLP-1 medications changed obesity treatment, but appetite regulation involves more than one hormonal signal. Cagrilintide is a long-acting analogue of amylin, a pancreatic peptide released alongside insulin that helps regulate satiety, gastric emptying, and post-meal glucagon signaling.

In this episode of Peptides Explained, John Garrett breaks down what cagrilintide is, how it differs from GLP-1 receptor agonists, what standalone phase 2 data show, and what the phase 3 CagriSema trials tell us about combining cagrilintide with semaglutide.

We also examine the REDEFINE 4 comparison with tirzepatide, common gastrointestinal adverse effects, unresolved questions about long-term outcomes and lean mass, and why online research products should not be treated as equivalent to the pharmaceutical trial material.

Cagrilintide remains investigational and is not currently an FDA-approved treatment. This content is educational and is not medical advice.

Peptides Explained is an affiliate partner with Offline Peptides. Research-use products are not approved medications and are not intended for human use.

Visit: PeptidesExplained.info/OfflinePeptides

For information on Compounded Peptides through Premier Pharmacy visit Peptide Solutions and submit a request for more information

Visit: Peptide-Solutions.info and submit a request for more information

Send a two- to three-minute N=1 video to [email protected].

AOD-9604 is often marketed as the "fat-burning fragment" of human growth hormone. But what does it actually do, and did it work in human obesity trials?

In this episode of Peptides Explained, John Garrett, RN, breaks down:

• What AOD-9604 is and how it differs from full-length HGH

• Lipolysis, lipogenesis, and beta-3 adrenergic signaling

• Why animal studies looked promising

• What the early human trials showed

• Why the obesity-development program was discontinued

• Whether AOD-9604 raises IGF-1

• Regulatory status, risks, unknowns, and anti-doping concerns

• A responsible framework for evaluating experimental fat-loss peptides

The central takeaway: AOD-9604 has a plausible preclinical mechanism, but the available human evidence does not establish dependable, clinically meaningful fat loss.

This episode is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any therapy.

This episode is brought to you by Offline Peptides. If you are interested in Research Peptides Learn more at

PeptidesExplained.info/OfflinePeptides.

For more information about Peptide Solutions, visit Peptide-Solutions.info.

Send your 2–3 minute N=1 video to [email protected].

SLU-PP-332 is being promoted as an "exercise mimetic" that may increase fat oxidation, endurance, and energy expenditure. But it is not actually a peptide, it is not FDA-approved, and the most compelling evidence comes from cell and mouse research—not human clinical trials.

In this episode, John Garrett, RN, explains estrogen-related receptors, mitochondrial energy metabolism, the published preclinical findings, the oral-bioavailability problem, potential risks, regulatory status, and the difference between mimicking selected exercise pathways and replacing physical exercise.

This content is for education and discussion only and is not medical advice. SLU-PP-332 is an experimental research compound with no established human therapeutic use.

Learn more: PeptidesExplained.info

Peptide Solutions: Peptide-Solutions.info

Offline Peptides: PeptidesExplained.info/OfflinePeptides

Affiliate disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

Send 2–3 minute N=1 videos to [email protected].

Why are Americans living longer than ever before while spending more years battling chronic disease?

In this episode of Peptides Explained, we explore one of the biggest questions in longevity medicine: the difference between lifespan and healthspan.

You'll learn why muscle loss, metabolic dysfunction, chronic inflammation, mitochondrial decline, immune aging, and cognitive changes are major drivers of aging—and where peptide research may fit into each of these biological systems.

We discuss several categories of peptides currently being investigated, including:

• Growth Hormone Secretagogues (Tesamorelin, Ipamorelin, Sermorelin, CJC-1295) • GLP-1 and Metabolic Peptides (Semaglutide, Tirzepatide, Retatrutide) • Anti-Inflammatory Peptides (KPV, Thymosin Alpha-1, BPC-157) • Regenerative Peptides (BPC-157, TB-500, GHK-Cu) • Nootropic Peptides (Semax, Selank, Dihexa) • Mitochondrial Peptides (MOTS-c, SS-31, Epitalon)

This episode discusses current science, emerging research, and where evidence is strong—and where it is still evolving.

This podcast is for educational purposes only and is not medical advice.

Sponsored by Peptide Solutions

Learn more: https://peptide-solutions.info

Research Peptides (Affiliate):

PeptidesExplained.info/OfflinePeptides

Affiliate Disclosure: Peptides Explained is an affiliate partner with Offline Peptides.

#Peptides #HealthyAging #Longevity #GLP1 #Retatrutide #Semaglutide #BPC157 #MOTSc #Healthspan #PeptidesExplained

NAD+ is one of the most talked-about molecules in longevity and wellness. It is marketed for energy, mitochondrial support, cellular repair, brain fog, recovery, and anti-aging.

But what happens when we bring cancer biology into the conversation?

In this episode of Peptides Explained, we break down the relationship between NAD+ and cancer in clear, responsible language. NAD+ is essential for normal cellular function, DNA repair, mitochondrial energy production, redox balance, and immune signaling. But cancer cells may also rely on NAD+ metabolism to support growth, survival, DNA repair, oxidative stress control, and possible treatment resistance.

This episode covers NAD+, NADH, NR, NMN, niacinamide, IV NAD+, NAMPT, PARP enzymes, DNA repair, cancer therapy, human evidence, preclinical evidence, and why active cancer or recent cancer changes the risk discussion.

This is not a hype episode and not a fear episode. The real answer is context.

NAD+ biology is real. The cancer concern is biologically plausible. The human evidence is incomplete.

This podcast is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy, supplement, peptide, injection, or infusion.

Peptides Explained is powered by Peptide Solutions.

Learn more: peptide-solutions.info

Affiliate disclosure: Peptides Explained is an affiliate partner with Offline Peptides . If you use my link, I may earn a commission at no additional cost to you.

PeptidesExplained.info/OfflinePeptides

#NAD #NADPlus #NMN #NR #CancerBiology #LongevityScience #Mitochondria #DNARepair #NAMPT #PARP #PeptidesExplained #PeptideScience

Description

Can a tiny peptide discovered nearly 50 years ago hold the key to better sleep?

In this episode of Peptides Explained, we explore Delta Sleep-Inducing Peptide (DSIP)—one of the most mysterious compounds in peptide research. Unlike many peptides discussed today, DSIP has no confirmed receptor, conflicting clinical data, and decades of unanswered questions.

In this episode you'll learn:

✔️ What DSIP is ✔️ How sleep is biologically regulated ✔️ The fascinating history of DSIP's discovery in the 1970s ✔️ Proposed mechanisms involving GABA, serotonin, dopamine, and the HPA axis ✔️ Human and animal research findings ✔️ Potential side effects and safety considerations ✔️ Why DSIP is not FDA approved and why no major medical organization recommends it for insomnia or other sleep disorders

This podcast is intended for educational purposes only and is not medical advice.

🌐 Peptide Solutions https://peptide-solutions.info

🧬 Research Peptides (Affiliate Partner) PeptidesExplained.info/OfflinePeptides

If you use my affiliate link, I may receive a commission at no additional cost to you.

📧 N=1: Your Real-World Results

Have you researched DSIP?

Send a 2–3 minute video describing your experience to:

[email protected]

You may be featured in a future episode.

#DSIP #SleepPeptide #Peptides #SleepScience #Insomnia #Longevity #PeptidesExplained #SleepResearch #Neuroscience #Biohacking

5-Amino-1MQ is often talked about in peptide circles, but it is not actually a peptide. It is a small-molecule NNMT inhibitor being studied for its potential role in nicotinamide metabolism, NAD⁺ biology, methylation, fat-cell function, insulin sensitivity, and liver metabolism.

In this episode, John Garrett breaks down the proposed mechanism behind 5-Amino-1MQ, why people are discussing it for fat loss and body composition, and what the current research actually shows.

The data is interesting, especially in preclinical studies involving adipocytes, diet-induced obese mice, glucose tolerance, insulin sensitivity, and fatty liver markers. But the human clinical evidence is still limited, and 5-Amino-1MQ is not FDA-approved for fat loss, obesity, metabolic disease, longevity, or body composition.

This episode takes a balanced look at the science, the grey-market reality, and how to think about emerging metabolic compounds responsibly.

This podcast is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Peptides Explained is powered by Peptide Solutions.

Peptides Explained is also an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

Offline Peptides affiliate link: https://offlinepeptides.com/ref/JohnGarrett/

Podcast website: https://peptidesexplained.info

Peptide Solutions: https://peptide-solutions.info

BPC-157 & TB-500 for Dogs: Healing, Recovery & the Current Science

Welcome to Episode 1 of the Peptides Explained Veterinary Series.

In this episode, we examine two of the most talked-about peptides in regenerative veterinary medicine—BPC-157 and TB-500.

We'll discuss what researchers currently know about these experimental peptides, why they're generating interest among veterinarians and dog owners, how they may influence tendon, ligament, muscle, and connective tissue repair, and where the evidence remains limited.

Whether you own an active family pet, a hunting dog, an agility competitor, or a working K9, this episode provides a balanced look at the science while separating evidence from online speculation.

Educational only. BPC-157 and TB-500 are experimental compounds and are not FDA-approved veterinary medications.

Learn more at https://peptide-solutions.info

Peptides Explained is an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

https://offlinepeptides.com/ref/JohnGarrett/

Have a real-world experience using peptides with your dog? Send a 2–3 minute horizontal video to [email protected] for a chance to be featured in our "N=1: Your Real-World Results" segment.